

Appointment

From: Azzam, Nidal [Azzam.Nidal@epa.gov]
Sent: 4/19/2018 3:51:35 PM
To: Azzam, Nidal [Azzam.Nidal@epa.gov]; Buckley, Timothy [Buckley.Timothy@epa.gov]; Gillespie, Andrew [Gillespie.Andrew@epa.gov]; Strynar, Mark [strynar.mark@epa.gov]; Washington, John [Washington.John@epa.gov]; Medina-Vera, Myriam [Medina-Vera.Myriam@epa.gov]; Biales, Adam [Biales.Adam@epa.gov]; Schumacher, Brian [Schumacher.Brian@epa.gov]; Bergman, Erica [Erica.Bergman@dep.nj.gov]; Lindstrom, Andrew [Lindstrom.Andrew@epa.gov]
CC: Everett, Adolph [Everett.Adolph@epa.gov]; Conetta, Benny [Conetta.Benny@epa.gov]; Maybury, Steve [Steve.Maybury@dep.nj.gov]; Migliarino, Maurice [Maurice.Migliarino@dep.nj.gov]
Subject: PFAS Fingerprinting Conference Call
Attachments: 923-SHARP4140@dep.nj_20180416_120642.pdf; 1-s2.0-S016041201300192X-main.pdf
Start: 4/26/2018 3:00:00 PM
End: 4/26/2018 4:00:00 PM
Show Time As: Busy

Required Attendees: Azzam, Nidal; Buckley, Timothy; Gillespie, Andrew; Lindstrom, Andrew; Strynar, Mark; Washington, John; Medina-Vera, Myriam; Biales, Adam; Schumacher, Brian; Bergman, Erica
Optional Attendees: Everett, Adolph; Conetta, Benny; Maybury, Steve; Migliarino, Maurice

Per ORD request, John Washington, an attachment has been added: "Fluorinated alternatives to long-chain perfluoroalkyl carboxylic acids (PFCAs), perfluoroalkane sulfonic acids (PFSA) and their potential precursors"

Below is the conference calling information and agenda.

Conference Calling

Number: Ex. 6 Personal Privacy (PP)

ID: Ex. 6 Personal Privacy (PP)

Draft Agenda

1. Current timing of release of results or draft Results Reports.
2. Status of NERL obtaining Standards for Solvay replacement compounds.
3. Field Sampling Plan and GenX analysis.
4. Can estimates be provided for chemicals detected that do not have Standards (Similar to TICs). This would be helpful to understand the magnitude compounds detected.
5. If high levels of a compound are detected in raw sample collected from a drinking water source, NJDEP will need additional analysis of post-treatment samples to evaluate effectiveness of treatment.
6. Presence of Precursors - Has NERL conducted or evaluated Total Oxidable Precursor essay on samples? Thoughts on the use? Future evaluation?
7. The attached list provides commercial labs that analyze for GenX. Why are there two CAS #s? And if this is correct what is the analytical difference?
8. Scheduling monthly conference calls.

